Sumanta K Pal Selected Research

Everolimus

1/2023	Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial.
1/2022	Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial.
1/2021	Gene Expression Signature Correlates with Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Everolimus Alone or with a Vascular Disrupting Agent.
4/2016	Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies.
4/2016	Real-World Effectiveness of Everolimus Subsequent to Different First Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Synthesis of Retrospective Chart Reviews.
1/2016	Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review.
1/2016	Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US.
6/2015	Exceptional Response on Addition of Everolimus to Taxane in Urothelial Carcinoma Bearing an NF2 Mutation.
4/2015	Prognostic factors for survival following initiation of second-line treatment with everolimus for metastatic renal cell carcinoma: evidence from a nationwide sample of clinical practice in the United States.
11/2014	Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: synthesis of findings from two multi-practice chart reviews in the United States.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sumanta K Pal Research Topics

Disease

148	Renal Cell Carcinoma (Grawitz Tumor) 04/2024 - 08/2011
100	Neoplasms (Cancer) 04/2024 - 09/2011
37	Prostatic Neoplasms (Prostate Cancer) 02/2024 - 09/2011
28	Carcinoma (Carcinomatosis) 10/2023 - 04/2015
26	Urinary Bladder Neoplasms (Bladder Cancer) 01/2024 - 12/2012
22	Neoplasm Metastasis (Metastasis) 04/2024 - 01/2012
18	Kidney Neoplasms (Kidney Cancer) 04/2024 - 05/2012
11	Disease Progression 01/2022 - 04/2016
6	Urogenital Neoplasms 10/2023 - 01/2017
5	Breast Neoplasms (Breast Cancer) 12/2012 - 01/2010
4	Circulating Neoplastic Cells 01/2021 - 05/2015
4	Melanoma (Melanoma, Malignant) 01/2021 - 01/2015
4	Fatigue 01/2020 - 01/2018
2	Brain Neoplasms (Brain Tumor) 01/2024 - 08/2023
2	Infections 12/2023 - 08/2023
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 06/2020
2	Hyperphosphatemia 12/2020 - 01/2018
2	Hypertension (High Blood Pressure) 01/2020 - 05/2012
2	Liver Neoplasms (Liver Cancer) 12/2019 - 05/2015
2	Hand-Foot Syndrome 10/2019 - 04/2018
2	Mucositis 10/2019 - 04/2018
2	Anemia 07/2017 - 04/2015
2	Diarrhea 12/2015 - 05/2012

Drug/Important Bio-Agent (IBA)

29	Immune Checkpoint InhibitorsIBA 04/2024 - 12/2017
22	Biomarkers (Surrogate Marker)IBA 12/2023 - 07/2013
18	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2023 - 01/2014
18	Sunitinib (Sutent)FDA Link 12/2022 - 02/2014
17	NivolumabIBA 01/2024 - 10/2017
15	Tyrosine Kinase InhibitorsIBA 01/2024 - 01/2014
14	Cisplatin (Platino)FDA LinkGeneric 01/2024 - 12/2012
13	IpilimumabIBA 12/2023 - 01/2015
11	cabozantinibIBA 01/2023 - 01/2019
10	Everolimus FDA Link 01/2023 - 11/2014
10	Androgen Receptors (Androgen Receptor)IBA 01/2020 - 01/2015
9	tivozanibIBA 01/2024 - 12/2012
9	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2024 - 07/2013
9	Sorafenib (BAY 43-9006)FDA Link 01/2023 - 05/2012
8	Circulating Tumor DNAIBA 01/2023 - 05/2017
8	PlatinumIBA 12/2021 - 01/2017
7	Gemcitabine FDA Link 01/2024 - 05/2013
7	Axitinib (AG 013736)IBA 01/2023 - 05/2012
7	Bevacizumab (Avastin)FDA Link 01/2021 - 10/2012
7	AndrogensIBA 04/2019 - 09/2011
6	infigratinibIBA 04/2024 - 01/2018
6	pazopanib FDA Link 03/2024 - 01/2017
6	atezolizumabIBA 11/2021 - 10/2017
6	Docetaxel (Taxotere)FDA Link 09/2021 - 11/2012
6	TOR Serine-Threonine KinasesIBA 06/2016 - 10/2014
5	ParaffinIBA 01/2023 - 05/2015
5	Formaldehyde (Formol)FDA Link 01/2023 - 05/2015
5	Cell-Free Nucleic AcidsIBA 01/2022 - 01/2018
5	RNA (Ribonucleic Acid)IBA 01/2022 - 07/2013
5	enzalutamideIBA 01/2021 - 04/2013
5	LigandsIBA 01/2021 - 01/2018
4	pembrolizumabIBA 10/2023 - 10/2017
4	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 01/2016
4	MTOR InhibitorsIBA 06/2016 - 11/2013
3	B7-H1 AntigenIBA 01/2022 - 01/2020
3	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 01/2022 - 01/2019
3	PPAR gammaIBA 01/2020 - 05/2018
3	CytokinesIBA 04/2019 - 01/2013
3	Proteins (Proteins, Gene)FDA Link 01/2019 - 01/2016
3	Toll-Like Receptor 9IBA 12/2018 - 12/2013
3	taxaneIBA 06/2015 - 01/2010
2	VaccinesIBA 01/2023 - 07/2013
2	AntibodiesIBA 01/2023 - 04/2015
2	Peptides (Polypeptides)IBA 01/2022 - 07/2013
2	Immunoconjugates (Immunoconjugate)IBA 01/2022 - 12/2014
2	Monoclonal AntibodiesIBA 01/2022 - 01/2015
2	CateninsIBA 02/2021 - 01/2019
2	Prednisone (Sone)FDA LinkGeneric 01/2021 - 01/2013
2	abirateroneIBA 01/2021 - 04/2019
2	Programmed Cell Death 1 ReceptorIBA 01/2021 - 10/2020
2	Type 1 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 1)IBA 12/2020 - 01/2018
2	avelumabIBA 11/2020 - 10/2017
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2018 - 04/2015
2	Warfarin (Coumadin)FDA LinkGeneric 02/2017 - 01/2017
2	temsirolimus FDA Link 04/2016 - 11/2014
2	cabazitaxel FDA Link 12/2015 - 12/2012
2	Prostate-Specific Antigen (Semenogelase)IBA 09/2015 - 01/2015
2	Doxorubicin (Adriamycin)FDA LinkGeneric 08/2015 - 12/2012
2	Methotrexate (Mexate)FDA LinkGeneric 08/2015 - 12/2012
2	Vinblastine (Vinblastine Sulfate)FDA Link 08/2015 - 12/2012
2	Toll-Like Receptors (Toll-Like Receptor)IBA 07/2015 - 01/2014

Therapy/Procedure

133	Therapeutics 03/2024 - 04/2010
38	Immunotherapy 04/2024 - 09/2011
21	Castration 02/2024 - 09/2011
20	Drug Therapy (Chemotherapy) 01/2023 - 04/2010
13	Nephrectomy 10/2023 - 06/2014
11	Cystectomy 11/2023 - 05/2013
6	Radiotherapy 01/2023 - 12/2013
5	Neoadjuvant Therapy 10/2020 - 05/2013
4	Adjuvant Chemotherapy 07/2022 - 03/2016
3	Metastasectomy 03/2024 - 01/2017
3	Precision Medicine 01/2021 - 01/2020
2	Organ Sparing Treatments 01/2024 - 11/2023
2	Drug Tapering 10/2021 - 04/2018
2	Prostatectomy (Retropubic Prostatectomy) 12/2018 - 01/2017
2	Chemoradiotherapy 04/2018 - 10/2016
2	Ligation 03/2016 - 01/2016